-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Decoding and Rewriting Immune Cells to Advance Immune Responses to Cancer.

Program: Scientific Program
Session: Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy
Sunday, December 10, 2023, 9:30 AM-11:05 AM

Alexander Marson, MD, PhD

University of California, San Francisco, San Francisco, CA

Disclosures: Marson: Arsenal Bioscience: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Other: Compensated co-founder; Spotlight Therapeutics: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Other: Compensated co-founder; Survey Genomics: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Other: Co-founder; NewLimit: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; PACT Pharma: Current equity holder in private company, Other: Speaking and/or advising fees; 23andMe: Other: Speaking and/or advising fees; June Therapeutics: Other: Speaking and/or advising fees; Research funding; Amgen: Other: Speaking and/or advising fees; Offline Ventures: Other: Investor, informal advisor; EPIQ: Other: Client; Gilead: Research Funding; Anthem: Research Funding; Tenaya Therapeutics: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Lighthouse Discovery Ltd: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees.

Previous Presentation | Next Presentation >>